AGOMAB THERAPEUTICS

agomab-therapeutics-logo

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

#SimilarOrganizations #People #Financial #Event #Website #More

AGOMAB THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Therapeutics

Founded:
2017-01-01

Address:
Ghent, Oost-Vlaanderen, Belgium

Country:
Belgium

Website Url:
http://www.agomab.com

Total Employee:
11+

Status:
Active

Email Addresses:
[email protected]

Total Funding:
236.96 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Tag Manager Apple Mobile Web Clips Icon Google Font API Google Analytics Google Maps WordPress


Similar Organizations

affimed-logo

Affimed

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

cedilla-therapeutics-logo

Cedilla Therapeutics

Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.

cellestia-logo

Cellestia

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.

pliant-therapeutics-logo

Pliant Therapeutics

Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.


Current Advisors List

thomas-a-wynn_image

Thomas A Wynn Board Member @ AgomAb Therapeutics
Board_member
2022-07-13

ohad-hammer_image

Ohad Hammer Board Member @ AgomAb Therapeutics
Board_member

john-haurum_image

John Haurum Chairman Of The Board @ AgomAb Therapeutics
Board_member
2019-04-01

felice-verduyn_image

Felice Verduyn Board Member @ AgomAb Therapeutics
Board_member

Current Employees Featured

virginia-morello_image

Virginia Morello
Virginia Morello Co-founder @ AgomAb Therapeutics
Co-founder

pierre-kemula_image

Pierre Kemula
Pierre Kemula Chief Financial Officer @ AgomAb Therapeutics
Chief Financial Officer
2024-01-01

tim-knotnerus_image

Tim Knotnerus
Tim Knotnerus Chief Executive Officer @ AgomAb Therapeutics
Chief Executive Officer

manuela-cazzanti_image

Manuela Cazzanti
Manuela Cazzanti Co-founder @ AgomAb Therapeutics
Co-founder

federica-linty_image

Federica Linty
Federica Linty Co-founder @ AgomAb Therapeutics
Co-founder

hans-de-haard_image

Hans De Haard
Hans De Haard Co-founder @ AgomAb Therapeutics
Co-founder

michael-saunders_image

Michael Saunders
Michael Saunders Co-founder @ AgomAb Therapeutics
Co-founder

not_available_image

Philippe Wiesel
Philippe Wiesel Chief Medical Officer @ AgomAb Therapeutics
Chief Medical Officer
2021-01-01

Founder


federica-linty_image

Federica Linty

hans-de-haard_image

Hans De Haard

manuela-cazzanti_image

Manuela Cazzanti

michael-saunders_image

Michael Saunders

virginia-morello_image

Virginia Morello

Acquisitions List

Date Company Article Price
2021-10-28 Origo Biopharma Origo Biopharma acquired by AgomAb Therapeutics N/A

Investors List

edmond-de-rothschild-investment-partners_image

Andera Partners

Andera Partners investment in Series C - AgomAb Therapeutics

redmile-group_image

Redmile Group

Redmile Group investment in Series C - AgomAb Therapeutics

pfizer_image

Pfizer

Pfizer investment in Series C - AgomAb Therapeutics

asabys-partners_image

Asabys Partners

Asabys Partners investment in Series C - AgomAb Therapeutics

fidelity-investments_image

Fidelity

Fidelity investment in Series C - AgomAb Therapeutics

dawn-biopharma_image

Dawn Biopharma

Dawn Biopharma investment in Series C - AgomAb Therapeutics

canaan-partners_image

Canaan Partners

Canaan Partners investment in Series C - AgomAb Therapeutics

pontifax_image

Pontifax

Pontifax investment in Series C - AgomAb Therapeutics

cormorant-asset-management_image

Cormorant Asset Management

Cormorant Asset Management investment in Series C - AgomAb Therapeutics

life-sciences-partners_image

EQT Life Sciences

EQT Life Sciences investment in Series C - AgomAb Therapeutics

Official Site Inspections

http://www.agomab.com Semrush global rank: 5.45 M Semrush visits lastest month: 1.36 K

  • Host name: 20.50.64.17
  • IP address: 20.50.64.17
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "AgomAb Therapeutics"

About Us – Agomab Therapeutics

The Agomab team has built a strong scientific foundation in targeting growth factors and modulating related molecular pathways through novel monoclonal antibodies and small molecule compounds to resolve fibrosis, regenerate …See details»

Agomab Therapeutics – Restoring Organ Function

Agomab Therapeutics NV (‘Agomab’) today announced positive interim results from 44 patients completing treatment in the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral …See details»

Agomab - LinkedIn

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function.See details»

AgomAb Therapeutics - Crunchbase Company Profile …

Agomab is a biotechnology company developing therapies that maintains and restores organ function in diseases characterized by fibrosis.See details»

Executive Committee – Agomab Therapeutics

Philippe joined Agomab as CMO in 2021. He was previously the CMO at Genkyotex where he led the company’s clinical development activities for the treatment of several fibrotic …See details»

AgomAb Therapeutics | Boehringer Ingelheim Venture Fund

Agomab is focused on achieving disease modification by modulating inflammation and fibrosis in chronic indications such as Fibrostenosing Crohn’s Disease and Idiopathic Pulmonary …See details»

Agomab Therapeutics - EQT Group

Agomab Therapeutics is a biotechnology company developing therapies that aim to preserve and restore organ function in fibrotic diseases.See details»

Agomab Therapeutics NV - Ghent, Belgium - bionity.com

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure, and restore organ function. By …See details»

AgomAb Company Profile - Office Locations, Competitors, …

AgomAb has 1 employees at their 1 location and $97.61 m in total funding,. See insights on AgomAb including office locations, competitors, revenue, financials, executives, subsidiaries …See details»

Agomab Therapeutics – Restoring Organ Function

Agomab Therapeutics NV (‘Agomab’) today announced that it has appointed David Epstein as non-executive board member and Chairman of its Board of Directors. David is an industry veteran and most recently served as Seagen’s …See details»

Agomab Therapeutics Completes Acquisition of Origo …

Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28 th, 2021, combines Spanish biotech Origo Biopharma and its pipeline of organ …See details»

Agomab Therapeutics to Acquire Origo Biopharma

A highly competent and committed organization. Agomab has built an impressive and driven R&D and corpor te team with access to high-quality resources. We are truly excited to take this step …See details»

Agomab Therapeutics to Acquire Origo Biopharma

Agomab will integrate these programs into its growing pipeline and add the entire Origo team and facilities to its current organization. As such, Agomab’s corporate footprint will comprise its …See details»

AgomAb Therapeutics - Funding, Financials, Valuation & Investors

Agomab is a biotechnology company developing therapies that maintains and restores organ function in diseases characterized by fibrosis.See details»

AgomAB Therapeutics - VentureRadar

"AgomAb is pioneering therapies that modulate regenerative pathways to achieve structural tissue repair and functional organ recovery. Our growing pipeline of highly specific monoclonal …See details»

Agomab - Asabys Partners

Agomab’s pipeline consists of its lead candidate AGMB-129, a gastrointestinal tract restricted ALK-5 inhibitor for the treatment of fibrostenotic Crohn’s disease. The second TGF-ß-targeting …See details»

Agomab raises $100m for Crohn’s drug, and other financings

4 days ago Agomab Therapeutics has closed a $100 million third-round financing, heading a list of recent funding rounds that also features AstronauTx, MinervaX, Precede Bio and …See details»

Pipeline – Agomab Therapeutics

Agomab aims to resolve these processes through a broad pipeline of small molecule and antibody drug candidates designed for their unique and novel modes of actions against well-validated …See details»

Agomab Therapeutics to Acquire Origo Biopharma - ASEBIO

Jan 19, 2022 Agomab Therapeutics NV (‘Agomab’) announced today that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage …See details»

FDA Approves Johnson & Johnson’s IMAAVY™ (nipocalimab-aahu) …

Apr 30, 2025 First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older. New York, April 30, 2025 – …See details»

linkstock.net © 2022. All rights reserved